AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01448109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile air filled vial
Description: the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days
Study NCT01515501 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic mucosal resection (EMR)
Description: EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
Study NCT04345068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm Meditation Mobile App
Description: The Calm app is downloadable by participants onto their smartphone. The Calm app is used to deliver the meditation intervention to experimental group participants.
Study NCT04345068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Podcast Mobile App
Description: The health education podcast mobile app mirrors the intervention group's app experience, but provides educational content via podcasts as an active comparator.
Study NCT01948024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAPHRIS
Description: 10 mg BID sublingual tablet
Study NCT01948024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 10 mg BID sublingual tablet
Study NCT00306475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: divalproex sodium ER
Description: divalproex sodium ER1000 mg
Study NCT00306475 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo identical in appearance to active comparator
Study NCT02429115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentoring
Description: Six months of peer-mentoring.
Study NCT03520036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117 low dose
Description: MT-7117 low dose QD, oral, 16 weeks
Study NCT03520036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117 high dose
Description: MT-7117 high dose QD, oral, 16 weeks
Study NCT03520036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD, oral, 16 weeks
Study NCT03683576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB001
Description: film-coated oral tablet
Study NCT03683576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated oral tablet
Study NCT03839550 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate +SHR-1210
Description: Apatinib mesylate tablets: 250 mg, orally once a day. Take about half an hour after a meal with warm water (the daily dose should be as much as possible.~SHR-1210: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks. A total of 6 months of treatment,starting 4-8 weeks after radical hepatic resection.
Study NCT03839550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic Arterial Infusion(HAI)
Description: Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment (the specific time interval depends on the recovery of liver function of the patient). The specific dosage regimen is 80-100 mg of epirubicin or 50 mg of epirubicin + oxaliplatin 50 mg per HAI treatment.
Study NCT01227421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
Study NCT01227421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
Study NCT01227421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, (2 tablets) twice daily with food for 5 days
Study NCT01943669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk™ device
Description: Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
Study NCT00764582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% levofloxacin ophthalmic solution
Description: Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery
Study NCT00764582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% moxifloxacin ophthalmic solution
Description: Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery
Study NCT02227706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVICEL® Fibrin Sealant
Description: EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
Study NCT02227706 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL® Absorbable Hemostat
Description: SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
Study NCT00266656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humatrope
Description: According to investigator's clinical practice and guided by the approved package insert
Study NCT04571437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine metronomic combined with Letrozole
Study NCT04571437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Letrozole daily alone
Study NCT01603836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bone allogaft with bone marrow concentrate
Description: In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
Study NCT00756795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: 5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis.
Study NCT02408861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02408861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT02408861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02408861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02408861 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02408861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT03210376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Assessment
Description: Pain assessment done at about 15, 45, and 90 minutes after surgery.
Study NCT03695107 — intervention group
Intervention type: DRUG
Intervention: Nifedipine controlled released tablets
Description: lower blood pressure
Study NCT01797692 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: geriatric assessment
Description: A single geriatric assessment with a geriatrician was proposed to patients and to control population.
Study NCT02296268 — intervention group
Intervention type: BEHAVIORAL
Intervention: Aerobic Exercise Screening and Prescription Clinic
Description: Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
Study NCT01586390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional treatment for ankle sprain using ankle cast
Description: Functional treatment for ankle sprain using ankle cast
Study NCT01586390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle sprain treated with removable ankle support
Description: Ankle sprain functionally treated with removable and adjustable ankle support
Study NCT01454947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS): Accountable Justifications
Description: Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
Study NCT04255498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
Study NCT01454947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback: Peer Comparison
Description: Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
Study NCT01454947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDS Order Sets: Suggested Alternatives
Description: Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
Study NCT01432860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person counseling
Description: The design is a 3 \[in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care\] X 7 \[baseline, 4, 8, 12, 16, 20, and 24 month follow-up\] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
Study NCT01432860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Workbook
Description: Participants will read a workbook and perform skills training exercises.
Study NCT01432860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Computer-Based Education
Description: Participants will receive their education from an interactive app designed for a tablet computer.
Study NCT03394807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaine injection to Transversus abdominis plane and rectus sheath
Study NCT04255498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
Study NCT03394807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection to Transversus abdominis plane and rectus sheath
Study NCT00372112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444
Description: GW642444H
Study NCT00372112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW642444
Description: GW642444H
Study NCT00372112 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered twice daily
Study NCT02348606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110
Study NCT02348606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Study NCT02145364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultherapy® treatment
Description: Microfocused ultrasound treatment
Study NCT05038423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5R Shared Leadership Program
Description: The manualised 5RS program aims to develop the leadership qualities of peer leaders by teaching them how to create, embody, advance, and embed a collective sense of 'us' in their teams. More specifically, 5RS consists of two key components that involve (1) implementing a structure of shared leadership, and (2) strengthening the identity leadership skills of the appointed peer leaders (Fransen et al., 2020).~Fransen, K., Haslam, S. A., Steffens, N. K., Mallett, C. J., Peters, K., Mertens, N., \& Boen, F. (2020). All for us and us for all: Introducing the 5R Shared Leadership Program. Psychology of Sport and Exercise, 51, 101762. https://doi.org/10.1016/j.psychsport.2020.101762 Haslam, S. A., Steffens, N. K., Peters, K., Boyce, R. A., Mallett, C. J., \& Fransen, K. (2017). A social identity approach to leadership development: The 5R program. Journal of Personnel Psychology, 16(3), 113-124. https://doi.org/10.1027/1866-5888/a000176
Study NCT05038423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-week structured walking program
Description: Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
Study NCT05038423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week structured walking program
Description: Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
Study NCT03296930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400 MG Oral Tablet,
Description: Interferon free direct acting antiviral drugs used for treatment of HCV.
Study NCT03296930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Interferon free direct acting antiviral drugs used for treatment of HCV.
Study NCT00543504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 2.5 mg/kg By Vein Over 90 Minutes.
Study NCT00543504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200 mg By Mouth Daily for 28 Days
Study NCT00543504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 50 mg By Mouth Daily for 28 Days.
Study NCT00543504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
Study NCT00543504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 250 mg By Mouth Daily for 21 Days.
Study NCT00543504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 12.5 mg orally daily for 4 weeks, then 2 weeks off.
Study NCT00543504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
Study NCT00629681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
Study NCT02922556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Study NCT02922556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Study NCT02202408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI2670
Description: Oral, Single Dose
Study NCT02202408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same shape as the experimental drug
Study NCT03578159 — intervention group
Intervention type: OTHER
Intervention: Chhatralaya
Description: Chhatralaya, home for children provide living resources along with spiritual practices.
Study NCT01050972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Cognitive, Relaxation, Exercise Therapy
Description: Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
Study NCT01829191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Test Lens A
Description: FDA-approved, non-marketed daily disposable soft contact lens, conventional design
Study NCT01829191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Test Lens C
Description: Daily disposable soft contact lens with new optical design
Study NCT03546192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent Influenza Vaccine
Description: 0.5-mL, Intramuscular, SH 2015 formulation
Study NCT02266225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle-integrated Functional Exercise
Description: Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
Study NCT01840501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42721458 (single dose)
Description: JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
Study NCT01840501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42721458 (multiple doses)
Description: JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
Study NCT01840501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (single dose)
Description: Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
Study NCT01840501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (multiple doses)
Description: Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
Study NCT02205814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasitibant- low dose
Description: Single intra-articular injection of low dose of fasitibant
Study NCT02205814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasitibant- intermediate dose
Description: Single intra-articular injection of intermediate dose of fasitibant
Study NCT02205814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasitibant- high dose
Description: Single intra-articular injection of high dose of fasitibant